International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022
Real-World Dosing Patterns of Eculizumab-Naïve and Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Ravulizumab in the US
Landing
Back to Conference Resources
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.